

Raludotatug deruxtecan (R-DXd) in Japanese patients with ovarian cancer: Subgroup analysis of a Phase 1 study

KYOTO

Heart of JAP

Kazuki Sudo¹, Erika P. Hamilton², Kenichi Harano³, Shigehisa Kitano⁴, Kazuhiro Takehara⁵, Alexander Philipovskiy⁶, Brian Rini⁷, David R. Spigel², Jie Lin⁸, Yasuyuki Okuda⁹, Amine Bensmaine⁸, Yusuke Myobatake⁸, Kathleen Moore¹⁰

¹National Cancer Center Hospital, Tokyo, Japan; ²Sarah Cannon Research Institute, Nashville, TN, USA; ³National Cancer Center Hospital East, Chiba, Japan; ⁴Japanese Foundation for Cancer Research, Tokyo, Japan; ⁵NHO Shikoku Cancer Center, Ehime, Japan; ⁶Florida Cancer Specialists and Research Institute, Lake Mary, FL, USA; ⁷Vanderbilt-Ingram Cancer Center, Nashville, TN, USA; ⁸Daiichi Sankyo, Inc., Basking Ridge, NJ, USA; ⁹Daiichi Sankyo Co., Ltd., Tokyo, Japan; ¹⁰Oklahoma University/Sarah Cannon Research Institute, Oklahoma City, OK, USA.

Presentation OS13-2

Declaration of interests

Research fund	scientific research fund □ contract □ donation other () □ N/A		Sponsor	Daiich	Sankyo, Inc.		
Name of lead presenter	Kazuki Sudo		Institution or company/position		National Cancer Center Hospital, Tokyo, Japan		
		No	lf yes, please s	pecify t	he name of company, organization, your status.		
Employee or adviser of company and/or profit-making organization		×					
Profit of stock		×					
Patent fee		×					
Lecturer fee		×					
Manuscript fee		×					
Research expenses from company		✓	NanoCarrier, Daiichi Sankyo, AstraZeneca, Pfizer, Amgen, PRA Health Scienc Takeda, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahwa NJ, USA				
Contributions or endowed chair		×					
Fees of testimony, judgment, comment, etc.		*					
Presents or other payment		×					
Representative of organization for clinical study receiving research expenses from company		×					



Background

- The emergence of platinum resistance in recurrent OVC is inevitable; these patients have a clear need for novel treatments¹
- Expression of CDH6 is observed in ~65 to 85% of patients with OVC^{2-4}
- Raludotatug deruxtecan (R-DXd) is an ADC comprising a humanized IgG1 antibody against CDH6, a stable linker selectively cleaved within tumor cells, and a membrane-permeable topoisomerase I inhibitor^{4,5}
- Early results from the ongoing Phase 1 trial (NCT04707248) in Japanese and US patients demonstrated an acceptable safety profile and early efficacy signal for R-DXd in heavily treated advanced OVC^{6,7}
- A subgroup analysis of Japanese patients with OVC is presented here (data cutoff: July 14, 2023)

ADC, antibody-drug conjugate; CDH6, cadherin 6; IgG1, immunoglobulin G1; OVC, ovarian cancer.


1. Richardson DL, et al. JAMA Oncol. 2023;9:851–859; 2. Bartolomé RA, et al. Mol Oncol. 2021;15:1849–1865; 3. Shintani D, et al. Gynecol Oncol. 2022;166(Suppl. 1):S116; 4. Suzuki H, et al. Mol Cancer Ther. 2024; 10:1158/1535-7163.MCT-23-0287. Online ahead of print; 5. Nakada T, et al. Chem Pharm Bull (Tokyo). 2019;67:173–185; 6. Hamilton EP, et al. J Clin Oncol. 2022;40(16 Suppl.):3002. 7. Moore KN, et al. Ann Oncol. 2023;34(Suppl. 2): Abstr 745MO.



R-DXd was designed with 7 key attributes

R-DXd is a CDH6-directed ADC composed of three parts:^{1–5}

- Humanized anti-CDH6 lgG1 mAb
- Topoisomerase I inhibitor payload (an exatecan derivative, DXd)
- Tetrapeptide-based cleavable linker covalently bonds the above components




Payload mechanism of action: topoisomerase I inhibitor ^{1,b}
High potency of payload ^{4,5,b}
High drug-to-antibody ratio of ≈8 ^{1,b}
Payload with short systemic half-life ^{4,b,c}
Stable linker-payload ^{4,5,b}
Tumor-selective cleavable linker ^{1,4,5,b}
Bystander antitumor effect ^{1,b}



^aImage is for illustrative purposes only; actual drug positions may vary. ^bThe clinical relevance of these features is under investigation. ^cBased on animal data.
ADC, antibody–drug conjugate; CDH6, cadherin 6; DXd, exatecan derivative; IgG1, immunoglobulin G1; mAb, monoclonal antibody.
1. Suzuki H, et al. *Mol Cancer Ther.* 2024; 10.1158/1535-7163.MCT-23-0287. Online ahead of print; 2. Hamilton EP, et al. *J Clin Oncol.* 2022;40(16 Suppl.):3002; 3. Moore KN, et al. *Ann Oncol.* 2023;34 (Suppl. 2):


Abstr 745MO; 4. Nakada T, et al. Chem Pharm Bull (Tokyo). 2019;67:173–185; 5. Ogitani Y, et al. Clin Cancer Res. 2016;22:5097–5108.

First-in-human Phase 1 study of R-DXd (NCT04707248)^{1,2}



Enrollment criteria:

- Advanced/metastatic OVC not amenable to SOC therapy
- ECOG PS 0-1
- Prior taxane and platinum-based chemotherapy
- No previous CDH6-targeting agents or ADCs with a linked topoisomerase I inhibitor
- Patients were not selected based on tumor CDH6 expression



Key primary objectives:

- Safety and tolerability
- Determine MTD and RDE
- ORR per RECIST v1.1 (dose expansion)

Key secondary objectives:

- PK: ADC, total anti-CDH6 antibody, and the DXd payload
- ORR per RECIST v1.1 (dose escalation)
- DOR, DCR, and CBR per RECIST v1.1
- Immunogenicity

This analysis included Japanese patients with OVC who received R-DXd at 4.8, 5.6, and 6.4 mg/kg^a

ADC, antibody-drug conjugate; CBR, clinical benefit rate; CDH6, cadherin 6; DCR, disease control rate; DOR, duration of response; ECOG PS, Eastern Cooperative Oncology Group performance status; IV, intravenous; MTD, maximum tolerated dose; ORR, objective response rate; OVC, ovarian cancer; PK, pharmacokinetics; Q3W, every 3 weeks; RDE, recommended doses for expansion; RECIST 1.1, Response Evaluation Criteria in Solid Tumors version 1.1; SOC, standard of care.





^a4.8–8.0 mg/kg R-DXd dose cohorts were initially prioritized for dose expansion due to a favorable benefit/risk profile. As of October 2022, the 8.0 mg/kg cohort was closed due to a higher incidence of serious and Grade ≥3 TEAEs and lack of a favorable benefit/risk ratio (6/15 [40.0%] patients experienced serious and Grade ≥3 TEAEs).

Baseline characteristics


	Overall ^a N=45	Japanese n=15		
Age, years, median (range) Age ≥65 years, n (%)	66 (42–82) 25 (55.6)	60 (42-76) 5 (33.3)		
Country, n (%) Japan United States	15 (33.3) 30 (66.7)	15 (100.0) 0		
ECOG PS, n (%) 0 1	18 (40.0) 27 (60.0)	8 (53.3) 7 (46.7)		
Platinum-resistant disease ^b , n (%)	40 (88.9)	13 (86.7)		
Number of prior systemic regimens, median (range)	4 (1–12)	4 (2-8)		
Received prior systemic therapy, n (%) Bevacizumab PARP inhibitor	29 (64.4) 29 (64.4)	9 (60.0) 11 (73.3)		
Tumor CDH6 expression H-score, median (range)	140.5 (0–250)	155.0 (0–213)		

Data cutoff: July 14, 2023. ^aOnly patients treated with ≥1 dose of R-DXd 4.8–6.4 mg/kg were included in this analysis and defined as the safety analysis cohort. ^bDefined as tumor progression during or <6 months after completion of prior platinum therapy. CDH6, cadherin 6; ECOG PS, Eastern Cooperative Oncology Group performance status; PARP, poly (adenosine diphosphate [ADP]-ribose) polymerase.



Patient disposition

Data cutoff: July 14, 2023



Treatment status n=15 N=45 12 (80.0) Ongoing study treatment, n (%) 30 (66.7) Discontinued from the study, n (%) 15 (33.3) 3 (20.0) **Progression**^b 8 (17.8) 1 (6.7) 5 (11.1) 2 (13.3) Adverse events Other 2 (4.4)^c 0 Duration on study treatment, weeks, 17.9 (3.0–114.9) 13.0 (3.0-54.6) median (range) Treatment duration, n (%) ≥6 months 10 (22.2) 3 (20.0) ≥12 months 1 (2.2) 1 (6.7)

Overall

Japanese



Data cutoff: July 14, 2023. ^aEnrollment ongoing. ^bProgressive disease per RECIST 1.1. ^cDeath (n=1) and informed consent withdrawn (n=1). One patient died following CTCAE Grade 5 stroke not related to treatment. CTCAE, Common Terminology Criteria for Adverse Events; OVC, ovarian cancer; RECIST 1.1, Response Evaluation Criteria in Solid Tumors version 1.1.

Efficacy of R-DXd

Confirmed ORR by RECIST v1.1 in Japanese patients with OVC was 50%, similar to the response reported in the overall cohort

	Overall n=38	Japanese n=12			
Confirmed ORR, % (95% CI) [n/N]	48.6 (31.9, 65.6) [18/37] ^e	50 (21.2, 78.9) [6/12]			
Best overall response ^a , n (%) CR PR SD Non-CR/non-PD Not evaluable	1 (2.6) 17(44.7) 18 (47.4) 1 (2.6) ^e 1 (2.6) ^f	1 (8.3) 5 (41.7) 6 (50.0) 0 0			
Disease control rate ^b , % (95% CI)	97.4 (86.2, 99.9)	100.0 (73.5, 100)			
Clinical benefit rate ^c , % (95% Cl)	50.0 (33.4, 66.6)	50.0 (21.1, 78.9)			
Median time to response, weeks (95% CI)	5.7 (5.3, 11.4)	5.9 (5.1, NE)			
Median DOR, months, (95% CI) Median follow-up, months (range)	11.2 (3.1, NE) 6.7 (1.4–16.8)	11.2 (2.4, NE) 8.1 (2.4–11.2)			
CA-125 response rate ^d , % (95% CI) [n/N]	46.7 (28.3, 65.7) [14/30]	44.4 (13.7, 78.8) [4/9]			
Median PFS ⁹ , months, (95% CI) Median follow-up, months (range)	8.1 (5.3, NE) 4.0 (0–25.1)	12.4 (5.3, NE) 2.8 (0–12.4)			


Data cutoff: July 14, 2023.

^aBOR of CR or PR (per RECIST V1.1) must be confirmed and maintained \geq 28 days. ^bCR + PR + SD (per RECIST V1.1) \geq 5 weeks. ^cCR + PR + SD (per RECIST V1.1) \geq 180 days. ^dCA-125 response is defined as \geq 50% reduction in CA-125 levels from baseline confirmed and maintained \geq 28 days (evaluable patients had baseline level \geq 2x ULN \leq 2 weeks prior to starting treatment). ^eOne patient with no target lesion at baseline was excluded from the ORR dataset. ^fOne patient discontinued and did not have a post-baseline assessment. ^gEvaluable population: Japanese subgroup, n=15 and overall cohort, N=45. The evaluable population for PFS included patients who received \geq 1 dose of study treatment.



BOR, best objective response; CA-125, cancer antigen 125; CI, confidence interval; CR, complete response; DOR, duration of response; NE, not estimable; ORR, objective response rate; OVC, ovarian cancer; PD, progressive disease; PFS, progression-free survival; PR, partial response; RECIST v1.1, Response Evaluation Criteria in Solid Tumors version 1.1; SD, stable disease; ULN, upper limit of normal.

Preliminary antitumor activity of R-DXd is promising in heavily pretreated patients with OVC




Data cutoff: July 14, 2023.

^aThe efficacy-evaluable population included patients who received ≥ 1 dose of study treatment and completed ≥ 1 post-baseline tumor assessment or discontinued treatment for any reason prior to the first post-baseline tumor assessment. Change from baseline in target tumor size was assessed per RECIST v1.1. ^bCR + PR + SD (per RECIST V1.1) ≥ 5 weeks. ^cIn the Japanese subgroup, 3 patients were recently enrolled and did not have any post-baseline scans to date. ^dIn the US subgroup, 1 patient had no measurable lesions at baseline; 1 patient discontinued treatment and had no post-baseline scan; and 4 patients had no post-baseline scans. Only patients with measurable disease at baseline and ≥ 1 post-baseline tumor scan were included in the waterfall plot.





Preliminary antitumor activity of R-DXd is promising in heavily pretreated Japanese patients with OVC




Data cutoff: July 14, 2023.

^aMedian follow-up for DOR: 8.1 months (range, 2.4–11.2). The efficacy evaluable population included patients who received ≥1 dose of study treatment and completed ≥1 post-baseline tumor assessment or discontinued treatment for any reason prior to the first post-baseline tumor assessment. Change from baseline in target tumor size was assessed per RECIST v1.1. Only patients with measurable disease at baseline and ≥1 post-baseline tumor scan were included in the spider plot. In the Japanese subgroup, 3 patients were recently enrolled and had no post-baseline scans.



CI, confidence interval; DOR, duration of response; NE, not estimable; OVC, ovarian cancer; PFS, progression-free survival; RECIST v1.1, Response Evaluation Criteria in Solid Tumors version 1.1; TTR time to response.

R-DXd treatment resulted in marked CA-125 reduction in both Japanese and US patients with OVC




Data cutoff: July 14, 2023.

^aThe CA-125 evaluable population included patients with a baseline CA-125 value and ≥1 post-baseline CA-125 value. *Patients were evaluable for a confirmed CA-125 response if they had a baseline CA-125 sample ≥2x ULN obtained ≤2 weeks prior to treatment initiation according to the GCIG criteria; CA-125 response was defined as a ≥50% reduction in CA-125 levels (confirmed and maintained for ≥28 days) from a pre-treatment sample.



CA-125; cancer antigen 125; CI, confidence interval; GCIG, Gynaecologic Cancer Intergroup; NE, not evaluable; OVC, ovarian cancer; PFS, progression-free survival; PR, progressive response; SD, stable disease; ULN, upper limit of normal.


R-DXd treatment resulted in a CA-125 reduction in heavily pretreated Japanese patients with OVC



Time from first dose of study drug (months)

Data cutoff: July 14, 2023.

The CA-125 evaluable population included patients who received ≥1 dose of study treatment and completed ≥1 post-baseline tumor assessment or discontinued treatment for any reason. Change from baseline in target tumor size was assessed per RECIST v1.1. Only subjects with measurable disease at baseline and ≥1 post-baseline tumor scan were included in the spider plot. In the Japanese subgroup, 3 patients were recently enrolled and had no post-baseline scans.





Overall safety summary

The safety profile in the Japanese subgroup was consistent with that of the overall cohort, which is deemed manageable

	Overall N=45	Japanese n=15
Any TEAE, n (%)	42 (93.3)	13 (86.7)
Grade ≥3	20 (44.4)	6 (40.0)
Treatment-related TEAE, n (%)	41 (91.1)	13 (86.7)
Grade ≥3	12 (26.7)	6 (40.0)
Grade 5	0	0
SAE, n (%)	11 (24.4)	3 (20.0)
Grade ≥3	10 (22.2)	2 (13.3)
Dose modifications, ^a n (%)		
Drug discontinuation	5 (11.1)	2 (13.3)
Dose interruption	14 (31.1)	5 (33.3)
Dose reduction	7 (15.6)	2 (13.3)



Safety: most common TEAEs (≥10%)^a related to R-DXd

	Overall cohort (N=45)						Japanese subgroup (n=15)						
Total ('	%)/Grade ≥3(%)	Grade ≥	:3	Grad	e 1–2	Í	(Grade 1–2	Grade ≥3	Tot	al (%)/Grade	e ≥3(%)	
Nausea		51.1/2.2				$\left[\right]$					80.0/0		
Vomiting		33.3/2.2				40.0/6.7							
Anemia		20.0/8.9				33.3/13.3							
Decreased appetite		22.2/0				33.3/0							
Malaise		13.3/0					33.3/0						
Alopecia		15.6/0				26	.7/0						
AST increased		8.9/0				20.0/0							
Platelet count decreased				13.3/4	4.4			20.0/6.	7				
Neutrophil count decreased		22.2/11.1					20.0/13	.3					
Diarrhea			26	6.7/ <mark>0</mark>				20.0/0					
ALT increased					6.7/0			13.3/ <mark>0</mark>					
Fatigue			35.6/ <mark>2.2</mark>					13.3/ <mark>0</mark>					
ILD					4.4/0			13.3/ <mark>0</mark>					
WBC decreased	T			I	4.4/2.2	↓ ↓		13.3/6.7					
100	80	60	40	20	Pat	0 0 tients	,	20	40	60	80	10	

Drug-related ILD (Grade 2) was reported in 1 patient in the Japanese subgroup treated with R-DXd 6.4 mg/kg




Conclusions

- R-DXd is the first CDH6-directed ADC to demonstrate promising efficacy in patients with heavily pretreated OVC who were not selected based on tumor CDH6 expression
- Efficacy of R-DXd treatment (4.8–6.4 mg/kg) was consistent between the Japanese subgroup and the overall cohort
 - 50% of patients in the Japanese OVC subgroup achieved an ORR: 1 CR and 5 PRs
 - Median DOR was 11.2 months^a
 - Median PFS was 12.4 months^b
- The safety profile of R-DXd in the Japanese subgroup was:
 - Manageable and consistent with the safety profile in the overall cohort
 - Consistent with the safety profile observed with other DXd ADCs^{1,2}
- These data support further clinical evaluation of R-DXd in patients with OVC
- A Phase 2/3 study of R-DXd in patients with platinum-resistant OVC, REJOICE-Ovarian01 (NCT06161025), has been initiated globally, including in Japan

Data cutoff: July 14, 2023.

^aMedian follow-up for DOR: 8.1 months (range, 2.4–11.2). ^bMedian follow-up for PFS: 2.8 months (range, 0–12.4).

ADC, antibody-drug conjugate; CDH6, cadherin 6; CR, complete response; DOR, duration of response; DXd, exatecan derivative; ORR, objective response rate; OVC, ovarian cancer; PFS, progression-free survival; PR, partial response.





Acknowledgements

- We thank the patients, their families, and their caregivers for their participation and the study staff for their contributions
- This study is sponsored by Daiichi Sankyo, Inc. In October 2023, Daiichi Sankyo entered into a global development and commercialization collaboration agreement with Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. Rahway, NJ, USA for raludotatug deruxtecan (R-DXd)
- Medical writing support was provided by Anna Atkinson, PhD, of BOLDSCIENCE[®], Inc, and was funded by Daiichi Sankyo, Inc.
- Editorial support was provided in accordance with Good Publication Practice Guidelines (https://www.ismpp.org/gpp-2022)



Copies of this presentation obtained through Quick Response (QR) Code are for personal use only and may not be reproduced without permission from the author of this material.

